MYCN and cancer: Currently, research has found that the construction of T-cell vaccines targeting cytotoxic T lymphocytes (CTL) recognition, including cancer testis antigens (MAGE and NY-ESO-1), MYCN 110, and surviving in NB antigens, can stimulate T cell-mediated immunity to some extent (53–55).